Graft-versus-host Disease, Relapse
Conditions
Keywords
GVHD, Relapse, Overall Survival
Brief summary
Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and treatment.
Detailed description
Infusion of mesenchymal stem cells at day of recovery after BMT for patients with AL, AA and MM for acute GVHD prophylaxis and treatment. Infusion at dose 1 cells mln/kg at day of white blood cells recovery.
Interventions
BIOLOGICALMesenchymal stem cells
Mesenchymal stem cells infusion
Sponsors
National Research Center for Hematology, Russia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* allogenic BMT from related or unrelated donor
Exclusion criteria
* Severe infection * Relapse * admission to ICU * refusal of research * patients with graft failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GVHD | Every 30 day for 1 year after BMT |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | Every 30 day for 1 year after BMT |
| Relapse-free survival | Every 30 day for 1 year after BMT |
| Infection rate | Every 30 day for 1 year after BMT |
Countries
Russia
Contacts
Primary ContactElena Parovichnikova, Prof MD PhD
Backup ContactLarisa Kuzmina, MD PhD
Outcome results
None listed